Literature DB >> 15501795

The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.

Lise Brandt1, Yasir A W Skeiky, Mark R Alderson, Yves Lobet, Wilfried Dalemans, Oliver C Turner, Randall J Basaraba, Angelo A Izzo, Todd M Lasco, Philip L Chapman, Steven G Reed, Ian M Orme.   

Abstract

A tuberculosis vaccine candidate consisting of a 72-kDa polyprotein or fusion protein based upon the Mtb32 and Mtb39 antigens of Mycobacterium tuberculosis and designated Mtb72F was tested for its protective capacity as a potential adjunct to the Mycobacterium bovis BCG vaccine in the mouse and guinea pig models of this disease. Formulation of recombinant Mtb72F (rMtb72F) in an AS02A adjuvant enhanced the Th1 response to BCG in mice but did not further reduce the bacterial load in the lungs after aerosol challenge infection. In the more stringent guinea pig disease model, rMtb72F delivered by coadministration with BCG vaccination significantly improved the survival of these animals compared to BCG alone, with some animals still alive and healthy in their appearance at >100 weeks post-aerosol challenge. A similar trend was observed with guinea pigs in which BCG vaccination was boosted by DNA vaccination, although this increase was not statistically significant due to excellent protection conferred by BCG alone. Histological examination of the lungs of test animals indicated that while BCG controls eventually died from overwhelming lung consolidation, the majority of guinea pigs receiving BCG mixed with rMtb72F or boosted twice with Mtb72F DNA had mostly clear lungs with minimal granulomatous lesions. Lesions were still prominent in guinea pigs receiving BCG and the Mtb72F DNA boost, but there was considerable evidence of lesion healing and airway remodeling and reestablishment. These data support the hypothesis that the coadministration or boosting of BCG vaccination with Mtb72F may limit the lung consolidation seen with BCG alone and may promote lesion resolution and healing. Collectively, these data suggest that enhancing BCG is a valid vaccination strategy for tuberculosis that is worthy of clinical evaluation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15501795      PMCID: PMC523007          DOI: 10.1128/IAI.72.11.6622-6632.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  24 in total

Review 1.  Beyond BCG: the potential for a more effective TB vaccine.

Authors:  I M Orme
Journal:  Mol Med Today       Date:  1999-11

2.  Boosting vaccine for tuberculosis.

Authors:  J V Brooks; A A Frank; M A Keen; J T Bellisle; I M Orme
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

3.  Evolution of WHO policies for tuberculosis control, 1948-2001.

Authors:  M C Raviglione; A Pio
Journal:  Lancet       Date:  2002-03-02       Impact factor: 79.321

4.  Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.

Authors:  C G Feng; U Palendira; C Demangel; J M Spratt; A S Malin; W J Britton
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

5.  Improving vaccines against tuberculosis.

Authors:  Warwick J Britton; Umaimainthan Palendira
Journal:  Immunol Cell Biol       Date:  2003-02       Impact factor: 5.126

Review 6.  Tuberculosis vaccine development: recent progress.

Authors:  I M Orme; D N McMurray; J T Belisle
Journal:  Trends Microbiol       Date:  2001-03       Impact factor: 17.079

7.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

8.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project.

Authors:  C Dye; S Scheele; P Dolin; V Pathania; M C Raviglione
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A.

Authors:  Joanna R Kirman; Tara Turon; Hua Su; Amy Li; Carl Kraus; John M Polo; John Belisle; Sheldon Morris; Robert A Seder
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis.

Authors:  Oliver C Turner; Randall J Basaraba; Ian M Orme
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

View more
  61 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein.

Authors:  Scott M Irwin; Angelo A Izzo; Steven W Dow; Y A W Skeiky; Steven G Reed; Mark R Alderson; Ian M Orme
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

3.  Tuberculosis vaccines: current progress.

Authors:  Ian M Orme
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 5.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

6.  Prime-boost vaccination strategy with bacillus Calmette-Guérin (BCG) and liposomized alpha-crystalline protein 1 reinvigorates BCG potency.

Authors:  K F Siddiqui; M Amir; N Khan; G Rama Krishna; J A Sheikh; K Rajagopal; J N Agrewala
Journal:  Clin Exp Immunol       Date:  2015-06-03       Impact factor: 4.330

7.  Recombinant Mycobacterium bovis BCG prime-recombinant adenovirus boost vaccination in rhesus monkeys elicits robust polyfunctional simian immunodeficiency virus-specific T-cell responses.

Authors:  Mark J Cayabyab; Birgit Korioth-Schmitz; Yue Sun; Angela Carville; Harikrishnan Balachandran; Ayako Miura; Kevin R Carlson; Adam P Buzby; Barton F Haynes; William R Jacobs; Norman L Letvin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys.

Authors:  Steven G Reed; Rhea N Coler; Wilfried Dalemans; Wilifred Dalemans; Esterlina V Tan; Eduardo C DeLa Cruz; Randall J Basaraba; Ian M Orme; Yasir A W Skeiky; Mark R Alderson; Karen D Cowgill; Jean-Paul Prieels; Rodolfo M Abalos; Marie-Claude Dubois; Joe Cohen; Pascal Mettens; Yves Lobet
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

9.  Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis.

Authors:  Zhou Xing; Christine T McFarland; Jean-Michel Sallenave; Angelo Izzo; Jun Wang; David N McMurray
Journal:  PLoS One       Date:  2009-06-10       Impact factor: 3.240

10.  Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose.

Authors:  Claus Aagaard; Truc Thi Kim Thanh Hoang; Angelo Izzo; Rolf Billeskov; JoLynn Troudt; Kim Arnett; Andrew Keyser; Tara Elvang; Peter Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2009-06-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.